Incyte vs Vertex Pharmaceuticals
Incyte (INCY) and Vertex Pharmaceuticals (VRTX) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $22.6B
- Last close
- $111.36
- 12 months
- +32.9%
- Market value
- $129B
- Last close
- $507.00
- 12 months
- +24.3%
At a glance
- By market value, Vertex Pharmaceuticals ($128.5B) is about 5.7 times Incyte ($22.6B).
- Over the last 12 months Incyte's share price moved +32.9% and Vertex Pharmaceuticals's +24.3%; against the S&P 500 that is +13.7 points and +5.2 points.
- In their last fiscal years Incyte kept 25.0% of revenue as net income and Vertex Pharmaceuticals 32.9%.
- In the last 90 days insiders reported 0 open-market purchases at Incyte and 0 at Vertex Pharmaceuticals; members of Congress disclosed 0 trades in Incyte and 2 in Vertex Pharmaceuticals.
- Next results: Incyte Oct 29, 2026, Vertex Pharmaceuticals Nov 2, 2026.
Share price over the last 12 months
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Incyte INCYNASDAQ · Biotechnology | Vertex Pharmaceuticals VRTXNASDAQ · Biotechnology | |
|---|---|---|
| Size and profitability | ||
| Market value | $22.6B | $129B |
| Revenue, last fiscal year | $5.14B | $12B |
| Net income, last fiscal year | $1.29B | $3.95B |
| Net marginNet income as a share of revenue | 25.0% | 32.9% |
| Free cash flow | $1.41B | $3.19B |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Incyte against
Common questions
How do Incyte and Vertex Pharmaceuticals compare in size?
Vertex Pharmaceuticals has the larger market value: Incyte $22.6B and Vertex Pharmaceuticals $129B, at the last close.
Whose share price rose more over the last 12 months, INCY or VRTX?
Over the last 12 months Incyte moved +32.9% and Vertex Pharmaceuticals +24.3%. Past price moves say nothing about the future.
Which has had more insider buying, Incyte or Vertex Pharmaceuticals?
Since 2006, Incyte insiders reported 503 open-market purchases against 52 for Vertex Pharmaceuticals. These are counts of what was filed, not a view on either stock.
Do members of Congress trade INCY or VRTX?
In the last 12 months, members of Congress disclosed 0 trades in Incyte (INCY) and 5 in Vertex Pharmaceuticals (VRTX).
When did insiders last buy INCY and VRTX?
Incyte: Mar 10, 2022. Vertex Pharmaceuticals: Aug 7, 2025.
See the record behind any of these
Each company page opens free with one real filing and the counts of the last 12 months. OQRO Pro adds the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Incyte pageVertex Pharmaceuticals pageRare insider trades this weekAll comparisons
https://oqro.io/compare/incy-vs-vrtx
